Decreased DBC1 expression is associated with poor prognosis in patients with non-muscle-invasive bladder cancer

Korean Journal of Urology

Volumn 54, Issue 9, 2013, Pages 631-637

  Shim, Ui Jae ^a   Lee, Il Seok ^a   Kang, Ho Won ^a   Kim, Jayoung ^b,c   Kim, Won Tae ^a   Kim, Isaac Yi ^d   Ryu, Keun Ho ^e   Choi, Yung Hyun ^f   Moon, Sung Kwon ^g   Kim, Yong June ^a   Yun, Seok Joong ^a   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e Chungbuk National University   (South Korea)

^f Dong Eui University   (South Korea)

^g Chung Ang University   (South Korea)

Author keywords

Bladder cancer; Human DBC1 protein; Prognosis

Indexed keywords

BCG VACCINE; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DBC1 GENE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 84884176406     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2013.54.9.631     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Lee JY, Joo HJ, Cho DS, Kim SI, Ahn HS, Kim SJ. Prognostic significance of substaging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder. Korean J Urol 2012;53:317-323.
3. Youssef RF, Lotan Y. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. Scientific World Journal 2011;11:369-381.
4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-42.
5. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-2330.
6. Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 2008;5:501-508.
7. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010;9:3.
8. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291-1294.
9. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006;176(4 Pt 1):1354-1361.
10. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-465.
11. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1-8.
12. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048.
13. Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):64-74.
14. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-219.
15. Stadler WM, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 2001;7:1676-1682.
16. Louhelainen JP, Hurst CD, Pitt E, Nishiyama H, Pickett HA, Knowles MA. DBC1 re-expression alters the expression of multiple components of the plasminogen pathway. Oncogene 2006;25: 2409-2419.
17. Fujiwara H, Emi M, Nagai H, Ohgaki K, Imoto I, Akimoto M, et al. Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell line. J Hum Genet 2001;46:372-377.
18. Habuchi T, Luscombe M, Elder PA, Knowles MA. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998;48:277-288.
19. Grønbaek K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, et al. Frequent hypermethylation of DBC1 in malignant lym-phoproliferative neoplasms. Mod Pathol 2008;21:632-638.
20. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M, et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005;14: 997-1007.
21. Nishiyama H, Gill JH, Pitt E, Kennedy W, Knowles MA. Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 2001;20:2956-2964.
22. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87:13-15.
23. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002;196:380-385.
24. Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, Blanca A, Quintero A, Montironi R, et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 2008;215:263-272.
25. Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001;20:531-537.
26. Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene 2004;23:82-90.